invest1 distinct publisher
Korea's P-CAB push in China is a reimbursement story, not an approval count
K-CAB added 402 Chinese hospitals in the first half and grew sales more than 30%. What holds its second place is NRDL coverage and a patent that outlasts Takeda's by 64 months.
Publishers:en.sedaily.com
Reality
- Evidence45
- Adoption72
- Hype gap+15
- Incentives62